Actively Recruiting
The Clinical Study on the Treatment of SSc With UTAA91 Injection.
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-07-18
24
Participants Needed
1
Research Sites
761 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.
CONDITIONS
Official Title
The Clinical Study on the Treatment of SSc With UTAA91 Injection.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older, any gender
- Expected survival time of 3 months or more
- Diagnosis of refractory moderate-to-severe active systemic sclerosis resistant to standard treatment or lacking effective options
- Adequate liver, kidney, and cardiopulmonary function
- No severe psychiatric disorders
- Able to understand the trial and provide informed consent
You will not qualify if you...
- History of malignant tumors, except relapsed/refractory autoimmune diseases within 5 years before screening
- Positive virology or syphilis test results
- Severe cardiac diseases or unstable systemic diseases
- Active or uncontrollable infections requiring systemic treatment
- Evidence of central nervous system invasion
- Pregnant or breastfeeding women, or those planning pregnancy within 2 years after treatment
- Male participants with partners planning pregnancy within 2 years after treatment
- Previous CAR-T or other gene-modified cell therapies before screening
- Participation in other clinical trials within 1 month before screening
- Any other condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
Q
Qiubai Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here